Ascendia Pharmaceuticals Named to Inc. 5000 List for Third Consecutive Year
Ascendia Pharmaceuticals is pleased to announce it has been named to the prestigious Inc. 5000 rankings of the fastest growing privately-owned companies in the United States for the third consecutive year. The ranking was earned based upon Ascendia’s 180% growth. The list represents the leading companies within the American economy’s independent small businesses. Inc. magazine’s list and its ranking are measured on the percentage of revenue growth rate from 2018 to 2021.
The ranking solidifies Ascendia’s position as a leading pharmaceutical contract formulation development and manufacturing organization (CDMO) for biologicals and gene deliveries, as well as small molecules. Ascendia was one of only 37 New Jersey companies to be included in the Inc. 5000 and was 40th in the health products industry.
“Our talented team at Ascendia has worked together to achieve tremendous success that is once again earned us an Inc. 5000 ranking. We expect to continue to grow, evident by the expansion of our state-of-the-art facility and 100% employee growth year-over-year. Ascendia is poised to offer more services to the pharmaceutical/biotech industry that will aid in our growth but more importantly help develop drugs to better treat society,” said Ascendia founder and CEO Jim Huang, Ph.D.
Each year the Inc. 5000 lists seemingly become more competitive. Many of those that have garnered a spot on the list have shown growth within their ratings and revenues. Together, the companies on the list have added more than 1.1 million jobs over the past three years.
Complete results of the Inc. 5000, including company profiles and an interactive database that can be sorted by industry, region, and other criteria, can be found on the Inc. website.